Landmark RxPONDER Trial Results

Publication in The New England Journal of Medicine confirms that tens of thousands of women with node-positive, early-stage breast cancer can avoid chemotherapy with the Oncotype DX® test.

NCCN Breast Cancer Guidelines

New NCCN Breast Cancer Guidelines recognize Oncotype DX Breast Recurrence Score® as the “preferred” and only multigene test to predict chemotherapy benefit in node-positive early-stage breast cancer
Making cancer care smarter.™